Tiberias Technology (HK) Limited (Tibtech)

Tiberias Technology (TibTech) Limited incorporated in Hong Kong since 2016, is a subsidiary company of Arbele Group, focused on the novel cancer biomarker and target, Cadherin(CDH)-17. To support clinical development of “first-in-class” CDH17-targeted immunotherapeutics, TibTech has developed proprietary tissue and blood-based cancer screening platforms for GI cancers. The tissue-based automated immunohistochemistry (IHC) platform aims to aid clinical and personal decision making in patients with GI diseases, while the blood-based immunoassay platform is a useful tool for non-invasive GI cancer screening.